Roche’s First Anti-TIGIT Data Support Dual Checkpoint Inhibition Strategy
Executive Summary
Tiragolumab plus Tecentriq increased response rates versus Tecentriq alone in a Phase II study, with the greatest benefit in PD-L1-high NSCLC. The combination regimen already is being test in Phase III.
You may also be interested in...
The (Non-COVID) Clinical Trial Hits And Misses Of 2020
Putting aside the coronavirus pandemic for a while, and turning to industry’s more bread and butter R&D activities, Scrip takes a look at the industry’s biggest clinical trial hits and misses of the year.
ESMO: Merck & Co Vibostolimab Data Are Another Validation Of TIGIT
A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.
Roche Pharma Chief Picks Out Pearls in Cancer Pipeline
Oncology is an area where the Swiss major has long been a dominant player, and Bill Anderson highlighted programs to Scrip which Roche hopes will help extend that dominance.
Need a specific report? 1000+ reports available
Buy Reports